ClinicalTrials.Veeva

Menu

Lower Extremity Peripheral Arterial Disease and Exercise Ischemia (CLASH)

R

Rennes University Hospital

Status

Completed

Conditions

Intermittent Claudication
Peripheral Arterial Diseases

Treatments

Other: Subsequent walking performance

Study type

Interventional

Funder types

Other

Identifiers

NCT02041169
13/34-914 (Other Identifier)
2013-A01381-44 (Other Identifier)
35RC13-9907-CLASH

Details and patient eligibility

About

Lower extremity peripheral arterial disease (LEPAD) is a highly prevalent chronic disease. Cardiovascular mortality of LEPAD patients at five years ranges between 18 to 30%. LEPAD is primarily caused by atherosclerosis that induces an inadequate blood flow to meet the tissues demand due to the narrowing of the arteries. An aggravation of the arterial lesions in LEPAD patients induces a worsening of patients' symptoms and a severe limitation of their walking capacity, contributing to an impairment of their quality of life. Despite maintaining a sufficient walking activity is essential for these patients, LEPAD patients lower their physical activity, which worsen the disease and potentially contribute to increase the risk of cardiovascular events and deaths.

In a recent study in LEPAD patients, we showed, from a one hour GPS recording, a high variability of the patients' walking capacity (i.e., walking distances between two stops induced by lower limbs pain). Results suggested that in most patients previous stop duration before each walk was a predictor parameter of this walking variability. Whether there is an optimal or minimal recovery time influencing the walking capacity in LEPAD patients has never been studied.

This study is a prospective, cross-sectional study in exercise pathophysiology.

The main goal is to determine, following a walk that induces ischemia, the influence of the recovery duration on the subsequent walking performance in LEPAD patients.

Secondary goals are :

  1. To determine the nature of the relationship between the recovery duration and subsequent walking performance.
  2. To study the relationship between exercise ischemia, pain evolution and previous recovery duration.
  3. To determine whether the experimental procedure influence the determination of an optimal of minimal recovery duration.
  4. To study the influence of recovery duration on walking capacity from community-based measurement.

Full description

It is expected to determine for the first time an optimal recovery duration that would maximize the walking capacity of LEPAD patients.

In the medium term :

  • To give indications to the LEPAD patients to manage their pain in the community without lower their physical activity.
  • To limit the functional decline of LEPAD patients.
  • To influence the quality of life and cardiovascular mortality. This would deserve furthers studies.

Enrollment

23 patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

  • Age ≥ 18 years old

  • Insured under the French social security system (according to French law)

  • Presence of lower-extremity peripheral artery disease, defined by:

    • A resting ankle-brachial index (ABI) ≤ 0.90
    • OR if resting ABI > 0.90 and < 1.00, a decrease in recovery ankle systolic pressure or in recovery ABI from treadmill exercise higher than 30% or 20%, respectively (AHA recommendations).
    • OR if resting ABI > 1.40, a toe pressure index ≤ 0.70
  • Maximal walking distance on treadmill (3.2 km/h, 10% grade) < 500m (a)

  • Complain of exertional lower limbs pain that can begin or not at rest, causes the participant to stop walking and relieves or lessens within 10 minutes of rest (assessed using the San Diego questionnaire AND confirmed during treadmill testing) (b)

    1. As assessed during the medical appointment.
    2. According to our inclusion criteria, patients' leg symptoms that fell within the following leg symptom categories could be included in the study:

    i) Intermittent claudication. Patients that experience exertional calf pain that does not begin at rest and that forces them to stop walking and that relieves or lessens within 10 minutes of rest; ii) Atypical exertional leg pain/stop. This category can encompass diverse situations of exertional leg symptoms. In the present study, patients in this category were included if they experience exertional pain that does not begin at rest and that forces them to stop walking, but that do not involve only the calf(s) but also thigh(s) and/or buttock(s). Further, the exertional leg pain relieves or lessens within 10 minutes of rest; iii) Leg pain on exertion and rest. In this category, patients sometimes experience exertional leg pain at rest when they are standing still or sitting. On exertion, patients also experience a walking pain as described above. As reminded by Criqui et al., this category of patients with "pain at rest" should not be confused with patients that experience "rest pain", which usually refers to patients with such severe advanced PAD that ischemic pain is present even at rest. Patients with ischemic rest pain were not included in the study.

Non-Inclusion criteria

  • Exercise limitation due to symptoms not related to an arterial insufficiency in the lower limbs (e.g., dyspnea, angina pectoris)
  • Contraindication for walking (Abdominal aortic aneurysm > 4 cm)
  • Myocardial infarction and no stroke in the last 3 months
  • Critical limb ischemia, amputation.
  • Pregnant women
  • Adult subject to legal protection (guardianship or tutelage measure) and persons deprived from their liberty (according to French law).
  • Patient living more than 50 km from the university hospital
  • Patient unable to understand the instructions of the study

Trial design

Primary purpose

Supportive Care

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

23 participants in 1 patient group

Subsequent walking performance
Experimental group
Description:
Subsequent walking performance
Treatment:
Other: Subsequent walking performance

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems